Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 6, 1996, Pages 661-666

  Kubota, Takahiro ^b   Chiba, Kan ^b   Ishizaki, Takashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MEPHENYTOIN;

ADULT; ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; MUTANT; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; EXONS; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; PHENOTYPE;

EID: 0030444707     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90214-3     Document Type: Article

References (28)

1. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
2. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
3. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in human. Biochemistry 1994;33:1743-52.
4. Bertilsson L, Henthorn T, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
5. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-9.
6. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
7. Koyama E, Sohn DR, Shin SG, Chiba K, Shin JG, Kim YH, et al. Metabolic disposition of imipramine in Oriental subjects: relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. J Pharmacol Exp Ther 1994;271:860-7.
8. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
9. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993;266:52-9.
10. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
11. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
12. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-7.
13. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995;40:481-5.
14. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
15. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
16. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
17. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994;269:15419-22.
18. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
19. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P4502C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656-61.
20. Brockmöller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron 4/exon 5 G→A-splice site mutation. Pharmacogenetics 1995;5:80-8.
21. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5:312-7.
22. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet 1994;26:59-70.
23. Brockmöller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994;27:216-48.
24. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
25. Sohn DR, Shin SG, Ishizaki T. S-Mephenytoin pharmacogenetics and its clinical implications in Asian ethnic populations. Asia Pac J Pharmacol 1994;9:287-301.
26. May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, et al. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin. Clin Pharmacol Ther 1990;48:286-95.
27. Flockhart DA, Clauw DJ, Sale EB, Hewett J, Woosley RL. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clin Pharmacol Ther 1994;56:398-405.
28. Kaisary A, Smith P, Jacqz E, McAllister CB, Wilkinson GR, Ray WA, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquin and mephenytoin as risk factors. Cancer Res 1987;47: 5488-93.